Investigational Drug Details
| Drug ID: | D305 |
| Drug Name: | Rimonabant |
| Synonyms: | Rimonabant |
| Type: | Chemical drug |
| DrugBank ID: | DB06155 |
| DrugBank Description: | Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression. |
| PubChem ID: | 104850 |
| CasNo: | 168273-06-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | Cc1c(n(nc1C(=O)NN1CCCCC1)c1c(Cl)cc(cc1)Cl)c1ccc(cc1)Cl |
| Structure: |
|
| InChiKey: | JZCPYUJPEARBJL-UHFFFAOYSA-N |
| Molecular Weight: | 463.796 |
| DrugBank Targets: | Cannabinoid receptor 1 antagonist; G-protein coupled receptor 55 |
| DrugBank MoA: | Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. |
| DrugBank Pharmacology: | In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo. |
| DrugBank Indication: | For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m<sup>2</sup>, or patients wih a BMI greater than 27 kg/m<sup>2</sup> with associated risk factors, such as type 2 diabetes or dyslipidaemia. |
| Targets: | CNR1 antagonist |
| Therapeutic Category: | Antialcoholic drug; CNS drug |
| Clinical Trial Progress: | Phase 3 terminated (NCT00577148: Company decision taken in light of demands by certain national health authorities) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0259 | NCT00576667 | Phase 3 | Terminated | No Results Available | January 2008 | May 18, 2016 | Details |
| L0260 | NCT00577148 | Phase 3 | Terminated | No Results Available | February 2008 | May 18, 2016 | Details |
| L0696 | EUCTR2007-003012-61-PT | Not applicable | Not Recruiting | No Results Available | 17/08/2007 | 19 March 2012 | Details |
| L0697 | EUCTR2007-003013-14-PT | Not applicable | Not Recruiting | No Results Available | 17/08/2007 | 11 September 2012 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S07 | Anti-lipogenesis | de novo lipogenesis; de novo lipogenesis; DNL; anti-lipogenic mechanisms; adipogenesis; anti-obesity | stearoyl-CoA desaturase 1 (SCD-1); Acetyl-coenzyme carboxylase; acyl-CoA carboxylase inhibitor (ACC inhibitor); stearoyl Coenzyme A desaturase inhibitor (SCD inhibitor); THR-beta selective agonist; DGAT2 inhibitor; FASN inhibitor | Aramchol; Firsocostat (GS-0976); VK-2809; ION 224 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03803 | 33860199 | ACS Pharmacol Transl Sci | Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice. | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | Details |
| A11942 | 30673308 | Can J Physiol Pharmacol | The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease. | Details |
| A15687 | 28759733 | Can J Physiol Pharmacol | Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin. | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | Details |
| A16481 | 28363784 | Chem Phys Lipids | The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | Details |
| A20218 | 26078820 | Oxid Med Cell Longev | Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease. | Details |
| A21321 | 25406988 | Lipids Health Dis | Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. | Details |
| A23682 | 23567085 | J Hepatol | Cannabinoid signaling and liver therapeutics. | Details |
| A23813 | 23452341 | Br J Clin Pharmacol | The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake. | Details |
| A25718 | 21510837 | Curr Top Med Chem | A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. | Details |
| A26364 | 20584230 | Int J Clin Pract | Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. | Details |
| A26437 | 20460921 | Dig Dis | Endocannabinoids and their role in fatty liver disease. | Details |
| A26478 | 20415685 | Diabetes Obes Metab | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | Details |
| A26771 | 19818116 | BMC Gastroenterol | Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. | Details |
| A27218 | 18956296 | Semin Liver Dis | Current and emerging therapies in nonalcoholic fatty liver disease. | Details |
| A33105 | 26681496 | Biol Psychiatry | Cannabinoid Transmission in the Hippocampus Activates Nucleus Accumbens Neurons and Modulates Reward and Aversion-Related Emotional Salience. | Details |
| A37142 | 19858584 | Saudi J Gastroenterol | Endocannabinoids and non-alcoholic steatohepatitis. | Details |
| A44806 | 27256522 | Clin Endocrinol (Oxf) | Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. | Details |